Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT) today announced that results of a clinical trial ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting: Our Bureau, Bengaluru Friday, January 9, 2026, 12:15 Hrs [IST] Shilp ...

As of Friday, January 09, Heron Therapeutics, Inc.’s HRTX share price has surged by 18.11%, which has investors questioning ...

The New Year brings with it a set of new laws in New York state that will impact health care services for cancer patients, ...

This dual-immunotherapy neoadjuvant treatment regimen is mainly intended for patients with resectable stage IIB to III colon ...

Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron” or the 'Company”), a commercial-stage biotechnology company, today announced ...

As they waited Wednesday night for another of his passages that would strike a real chord in them — this one unfortunately like no other — some of the assembled police officers thought of another one ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...

Understand the role of reproductive biotech in overcoming biological limits in fertility treatments and enhancing success ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

A social media user and cancer patient, Mensah Omolola, popularly known on X as AuntieEsther, has died after weeks of public ...